ZA91574B - Use of n-myristoyl-(s)-phenylalanine for obtaining medicinal products for the treatment of diseases involving myristoylation - Google Patents

Use of n-myristoyl-(s)-phenylalanine for obtaining medicinal products for the treatment of diseases involving myristoylation

Info

Publication number
ZA91574B
ZA91574B ZA91574A ZA91574A ZA91574B ZA 91574 B ZA91574 B ZA 91574B ZA 91574 A ZA91574 A ZA 91574A ZA 91574 A ZA91574 A ZA 91574A ZA 91574 B ZA91574 B ZA 91574B
Authority
ZA
South Africa
Prior art keywords
myristoyl
phenylalanine
treatment
myristoylation
diseases involving
Prior art date
Application number
ZA91574A
Other languages
English (en)
Inventor
Michel Vincent
Vincent Michel
Georges Remond
Remond Georges
Yolande Herve
Herve Yolande
Jean-Albert Boutin
Boutin Jean-Albert
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Publication of ZA91574B publication Critical patent/ZA91574B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/005Enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA91574A 1990-01-25 1991-01-25 Use of n-myristoyl-(s)-phenylalanine for obtaining medicinal products for the treatment of diseases involving myristoylation ZA91574B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9000834A FR2657259A1 (fr) 1990-01-25 1990-01-25 Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation.

Publications (1)

Publication Number Publication Date
ZA91574B true ZA91574B (en) 1991-11-27

Family

ID=9393082

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA91574A ZA91574B (en) 1990-01-25 1991-01-25 Use of n-myristoyl-(s)-phenylalanine for obtaining medicinal products for the treatment of diseases involving myristoylation

Country Status (14)

Country Link
US (1) US5164414A (xx)
EP (1) EP0443891B1 (xx)
JP (1) JPH0717503B2 (xx)
AT (1) ATE94387T1 (xx)
AU (1) AU633395B2 (xx)
CA (1) CA2034861A1 (xx)
DE (1) DE69100364T2 (xx)
DK (1) DK0443891T3 (xx)
ES (1) ES2060310T3 (xx)
FR (1) FR2657259A1 (xx)
IE (1) IE65573B1 (xx)
OA (1) OA09478A (xx)
PT (1) PT96571A (xx)
ZA (1) ZA91574B (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672598A1 (fr) * 1991-02-11 1992-08-14 Adir Nouveaux inhibiteurs de n-myristoyltransferase, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5859052A (en) * 1993-01-14 1999-01-12 G. D. Searle & Co. Fatty acid analogs and prodrugs
US5599947A (en) * 1993-01-14 1997-02-04 G. D. Searle & Co. Fatty acid analogs and prodrugs
US6127393A (en) * 1995-12-29 2000-10-03 Novactyl, Inc. Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method
US6407125B1 (en) 1995-12-29 2002-06-18 Novactyl, Inc. Pharmacological agent and method of treatment
US6579891B1 (en) 1995-12-29 2003-06-17 Novactyl, Inc. Agent and method for prevention and treatment of cancer in animals
US6743771B2 (en) 1995-12-29 2004-06-01 Novactyl, Inc. Methods and compositions for controlling protein assembly or aggregation
US6441009B1 (en) 1998-08-01 2002-08-27 Novactyl, Inc. Agent and method of preventing and treating heavy metal exposure and toxicity
EP1220669A4 (en) * 1999-10-13 2004-12-08 Marco A Chacon THERAPEUTIC MEASURE TO IMPROVE THE EFFECT OF A CALORY RESTRICTION
US6403618B1 (en) 2000-02-15 2002-06-11 Novactyl, Inc. Agent and method for controlling angiogenesis
WO2003007876A2 (en) * 2001-06-25 2003-01-30 University Of Massachusetts N-fatty acid-amino acid conjugates and therapeutic uses
DE10353806A1 (de) * 2003-11-14 2005-07-07 Bundesrepublik Deutschland, vertreten durch das Bundesministerium für Gesundheit, dieses vertreten durch das Robert-Koch-Institut, vertreten durch seinen Präsidenten Verwendung von Aminosäure- und Zucker-Amphiphilen zur Inaktivierung von lipidumhüllten Viren
US7544714B2 (en) * 2004-07-16 2009-06-09 University Of Massachusetts Lipid-amino acid conjugates and methods of use
IL172896A0 (en) * 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
WO2013013302A1 (en) * 2011-07-22 2013-01-31 Pacylex Pharmaceuticals Inc. Synthetic lethality and the treatment of cancer
JP6209588B2 (ja) 2012-03-30 2017-10-04 ジボダン エス エー 食品フレーバー付与化合物としてのn−アシルプロリン誘導体
US10582715B2 (en) 2012-03-30 2020-03-10 Givaudan Sa Powder flavour composition
CN104244734B (zh) 2012-03-30 2018-04-03 奇华顿股份有限公司 作为食品加香化合物的n‑酰化1‑氨基环烷基羧酸
JP6250029B2 (ja) 2012-03-30 2017-12-20 ジボダン エス エー 食品フレーバー付与化合物としてのn−アシル−アミノ酸誘導体
CN104219965B (zh) 2012-03-30 2018-10-12 奇华顿股份有限公司 作为食品加香化合物的γ氨基-丁酸和β丙氨酸的N-酰基衍生物
CN104254253B (zh) 2012-03-30 2017-12-29 奇华顿股份有限公司 作为食品加香化合物的n‑酰化甲硫氨酸衍生物
JP6224072B2 (ja) 2012-03-30 2017-11-01 ジボダン エス エー フレーバープロフィール食用組成物の改良のためのn−アシル−アミノ酸誘導体
CN110974967B (zh) * 2012-10-30 2023-11-07 厄尔莱克斯制药公司 合成致死与癌症的治疗
WO2015048991A1 (en) 2013-10-02 2015-04-09 Givaudan Sa Organic compounds having taste-modifying properties
US10674755B2 (en) 2013-10-02 2020-06-09 Givaudan S.A. Organic Compounds
GB201317424D0 (en) 2013-10-02 2013-11-13 Givaudan Sa Improvements in or relating to organic compounds
WO2015050535A1 (en) 2013-10-02 2015-04-09 Givaudan S.A. Organic compounds
CN105636934B (zh) 2013-10-02 2019-03-29 奇华顿股份有限公司 N-酰化的2-氨基异丁酸化合物和包含它们的香味组合物
CN105636457B (zh) 2013-10-02 2020-03-10 奇华顿股份有限公司 具有味道改进特性的有机化合物
US10834950B2 (en) 2013-10-02 2020-11-17 Givaudan S.A. Organic compounds
WO2015050537A1 (en) 2013-10-02 2015-04-09 Givaudan S.A. Organic compounds
ES2964607T3 (es) 2015-07-17 2024-04-08 Pacylex Pharmaceuticals Inc Silenciamiento epigenético de NMT2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778878A (en) * 1986-08-07 1988-10-18 Washington University Novel inhibitor peptides I
US4778877A (en) * 1986-08-07 1988-10-18 Washington University Novel inhibitor peptides II

Also Published As

Publication number Publication date
DE69100364D1 (de) 1993-10-21
FR2657259B1 (xx) 1994-08-19
IE65573B1 (en) 1995-11-01
US5164414A (en) 1992-11-17
OA09478A (fr) 1992-11-15
DK0443891T3 (da) 1993-12-27
DE69100364T2 (de) 1994-04-21
IE910242A1 (en) 1991-07-31
AU6998791A (en) 1991-08-01
JPH0717503B2 (ja) 1995-03-01
ATE94387T1 (de) 1993-10-15
JPH04210916A (ja) 1992-08-03
ES2060310T3 (es) 1994-11-16
FR2657259A1 (fr) 1991-07-26
PT96571A (pt) 1991-10-15
EP0443891A1 (fr) 1991-08-28
AU633395B2 (en) 1993-01-28
CA2034861A1 (fr) 1991-07-26
EP0443891B1 (fr) 1993-09-15

Similar Documents

Publication Publication Date Title
ZA91574B (en) Use of n-myristoyl-(s)-phenylalanine for obtaining medicinal products for the treatment of diseases involving myristoylation
PL297610A1 (xx)
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
AU1808488A (en) Compounds for the treatment of alzheimer's disease
MY138883A (en) Use of asiatic acid for treatment of cencer
HUP9904317A3 (en) Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases
IL99778A0 (en) Compositions for the treatment of cell proliferation disorders
FR2651435B1 (xx)
IL115320A0 (en) Retinoyloxy (substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases
NO913117L (no) Fremgangsmaate for behandling av benoedeleggende sykdommer.
ZA929879B (en) Compositions for the treatment of mammalian diseases.
AU8204182A (en) Apparatus for the medical treatment of living organisms, particularly human beings
AU6491890A (en) Use of arylalkylamides in the treatment of neurodegenerative diseases
ZA893310B (en) Novel strobilurine derivatives,their preparation and their use
HK44597A (en) Use of chlormethiazole in the manufacture of a medicament for the prevention and/or treatment of neurodegeneration
GR3005231T3 (xx)
AP9000180A0 (en) Pharmaceutical composition for the treatment of protozoal diseases
GB2015873B (en) Medical treatment chair
ES1022564Y (es) Armonizador electromagnetico de las alteraciones fisiologicas del cuerpo humano.
DE3373907D1 (en) N-acyl derivatives of dipeptides, their manufacture and use in treating diseases, and means therefor
GB9010389D0 (en) Pharmaceutical formulations for the treatment of peripheral vascular diseases
AU7231191A (en) Compounds and methods for the treatment and diagnosis of cancer
PT94432A (pt) Processo para a producao sulfonamidas substituidas e compostos afins uteis no tratamento da asma, artrite e doencas afins
CS420590A3 (en) Apparatus for the protection of human body organs against ionizing radiation
OA09676A (en) Use of trinitrobenzenes or carminic acid in the treatment of cancer or viral diseases